Announcement IL

Ozempic and Vision Loss: What the FDA’s New NAION Warning Means in Illinois

Announcement from a bar association

Headline as published by Illinois Lawyer Now (ISBA) on Nov 16, 2026; collected by the wire Nov 16, 2026, 1:16 PM ET.

Read at Illinois Lawyer Now (ISBA)

On November 9, 2026, the FDA ordered every company that sells a GLP-1 drug to add a new warning to its label: a possible increased risk of NAION, a rare eye condition that can cause sudden and sometimes permanent vision loss. The order covers Ozempic, Wegovy, Mounjaro, Zepbound and every other GLP-1 on the market.... Continue Reading

From Illinois Lawyer Now (ISBA)’s feed

Coverage

  1. Illinois Lawyer Now (ISBA) Bar associations

    Ozempic and Vision Loss: What the FDA’s New NAION Warning Means in Illinois

Named in this story

Topics

Explore the named firms, organizations and MDL dockets above. Sources and method

MDL No. 3163

GLP-1 Vision Loss (NAION)

IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation

Transferee judge
Karen S. Marston
Court
Eastern District of Pennsylvania
Actions pending
247

Per the JPML pending-dockets report of October 1, 2026.